Anti-NKG2A/CD94 Antibody (Monalizumab)
Catalog No.
F1094
Anti-NKG2A/CD94 Antibody (Monalizumab)
Featured Products
Monalizumab (IPH2201) is a novel anti-cancer drug targeting natural killer cell cluster 2A (Monalizumab is a humanized anti-NKG2A monoclonal antibody that increases IFN-γ production, thereby promoting natural killer cell function. Monalizumab is used in the study of head and neck squamous cell carcinoma (HNSCC).
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1228763-95-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
IPH 2201, NN8765, NNC141-0100
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P26715
Human
Unconjugated
Monoclonal
Protein A
IgG4
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human NKG2A/CD94 HEK293 cells were stained with Anti-NKG2A/CD94 Antibody (Monalizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS
NKG2A / CD94
Please avoid freeze-thaw cycles.